US proposes rule to let states import some Canadian prescription drugs

Food and Drug Administration cites need for lower prices and reduced out-of-pocket costs to U.S. patients.

The U.S. Food and Drug Administration has proposed a rule that, if implemented, would allow states to import certain prescription drugs from Canada. [Photo Credit: Shutterstock]

The U.S. Food and Drug Administration has proposed a rule that, if implemented, would allow states to import certain prescription drugs from Canada.

“The purpose of the proposed rule is to lower prices and reduce out of pocket costs for American patients,” the FDA said in a Federal Register notice expected to be published on Dec. 23.

Under the rule, the program would be implemented through the Federal Food, Drug, and Cosmetic (FD&C) Act’s Section 804 Importation Programs (SIPs) and managed by states or certain non-federal entities. A pharmacist or wholesaler could co-sponsor a SIP.

Each eligible prescription drug import must be approved for use in both Canada and the U.S. and include appropriate labeling.

“The supply chain for each drug under a SIP would be limited to three entities, i.e. one manufacturer, one foreign seller, and one importer,” FDA said.

After the FDA approves a SIP, the U.S. importer must submit a “pre-import request” to the agency at least 30 days before the scheduled date of the prescription drug’s delivery. FDA will dictate at which Customs and Border Protection (CBP) port of entry the drug will arrive in the U.S.

The U.S. importer or its customs broker would be required to electronically file a formal import entry in the CBP’s Automated Commercial Environment (ACE).

“As drug distributors realize savings in acquiring imported drugs and pass some of these savings to consumers and other parties in the drug supply chain, it is possible that U.S. drug manufacturers may experience a transfer in U.S. sales revenues to these parties,” FDA said.

FDA will accept public comments regarding the proposed rulemaking for 75 days after publication in the Federal Register.

Canadians are concerned that the implementation of the FDA regulation will exacerbate a domestic shortage of certain prescription drugs. 

FreightWaves Canadian correspondent Nate Tabak reported in August that a 2018 survey found 67% of Canadian pharmacists dealt with daily shortages of certain prescription medicines.


Upcoming FreightWaves Events
AI

Supply Chain AI Symposium

Past the hype. Join operators, founders, and enterprise leaders figuring out how to deploy AI in supply chain.

July 15, 2026
The Old Post • Chicago, IL
Register Now
FreightTech

F3: Future of Freight Festival

Industry-defining keynotes, rapid-fire technology demos, and industry leaders networking in experiences across Chattanooga - plus the inaugural F3 Awards Dinner featuring the FreightTech and Shipper of Choice reveals.

October 27, 2026 – October 28, 2026
The Signal at Chattanooga Choo Choo • Chattanooga, TN
Register Now
AI Supply Chain AI Symposium Jul 15 • The Old Post • Chicago, IL

Past the hype. Join operators, founders, and enterprise leaders figuring out how to deploy AI in supply chain.

The Old Post • Chicago, IL Register Now
FreightTech F3: Future of Freight Festival Oct 27 – Oct 28 • The Signal at Chattanooga Choo Choo • Chattanooga, TN

Industry-defining keynotes, rapid-fire technology demos, and industry leaders networking in experiences across Chattanooga - plus the inaugural F3 Awards Dinner featuring the FreightTech and Shipper of Choice reveals.

The Signal at Chattanooga Choo Choo • Chattanooga, TN Register Now

Chris Gillis

Located in the Washington, D.C. area, Chris Gillis primarily reports on regulatory and legislative topics that impact cross-border trade. He joined American Shipper in 1994, shortly after graduating from Mount St. Mary’s College in Emmitsburg, Md., with a degree in international business and economics.